CD5 and myeloid sarcoma: Next, in 114 paired serum and CSF samples of people with MS, we applied PEA technology, a high-throughput multiplex proteomic immunoassay,16 with a panel of 92 immune-related proteins including CD5 (see Supplementary Table 3 for the complete panel).